What is the cure rate of larotrectinib?

Larotrectinib is a targeted therapy drug targeting NTRK gene fusion. It is mainly used to treat a variety of NTRK gene fusion-positive tumors, including soft tissue sarcoma, neuroblastoma, lung cancer, etc. Although it does not completely cure all patients, its clinical data shows that it shows significant efficacy in many patients.

In a multi-center clinical study, larotrectinib achieved a response rate (ORR) of up to 79% in all patients with NTRK fusion-positive tumors. Among them, 16% of patients achieved complete remission, and 63% achieved partial remission. For pediatric patients, larotrectinib is more effective, with a response rate as high as 92%. These study results show that larotrectinib has a high efficacy in the treatment of NTRK fusion-positive tumors, especially for those cases that are ineffective with traditional treatments.

Although larotrectinib performs well in terms of response rates and disease control, it cannot yet be claimed that it cures all patients. The therapeutic effect of larotrectinib is usually manifested as long-term remission, and the progression-free survival (PFS) of some patients can be as long as several years. Studies have shown that the median progression-free survival is 28.3 months, and the median overall survival (OS) is 44.4 months, indicating that larotrectinib has a significant effect on prolonging patients' survival and improving quality of life.

The therapeutic efficacy of larotrectinib varies across different tumor types and patient populations. In some complex cases, such as patients with brain metastases and central nervous system tumors, larotrectinib's response rate ranges from 30% to 75%, demonstrating its potential in these special groups.

Overall, larotrectinib provides a new treatment option for patients with NTRK fusion-positive tumors, especially with significant advantages in the treatment of refractory and advanced patients. Although it cannot completely cure all patients, larotrectinib is still an effective treatment option for patients with this type of tumor, providing hope especially for those patients who have failed traditional treatments.

xa0

Reference materials:

1.HealthNews, "Larotrectinib: A Promising Treatment for NTRK Fusion Cancer,"

https://www.healthnews.com

2.CN Healthcare, "Larotrectinib Long-Term Efficacy Data in TRK Fusion Cancers,"

https://www.cn-healthcare.com